Shares of Cardiovascular Systems, Inc. (NASDAQ:CSII) have been given a consensus rating of “Hold” by the nine ratings firms that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $34.40.
A number of equities research analysts recently commented on CSII shares. Needham & Company LLC reissued a “buy” rating and issued a $32.00 price objective on shares of Cardiovascular Systems in a research note on Tuesday, April 18th. TheStreet raised shares of Cardiovascular Systems from a “d” rating to a “c-” rating in a research note on Thursday, May 4th. BidaskClub raised shares of Cardiovascular Systems from a “hold” rating to a “buy” rating in a research note on Friday, June 9th. Bank of America Corporation cut shares of Cardiovascular Systems from a “neutral” rating to an “underperform” rating in a research note on Wednesday, June 21st. Finally, Zacks Investment Research cut shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a research note on Friday.
Shares of Cardiovascular Systems (NASDAQ CSII) traded down 0.26% during mid-day trading on Friday, hitting $30.94. 127,185 shares of the stock traded hands. The firm’s 50 day moving average price is $31.80 and its 200 day moving average price is $29.39. Cardiovascular Systems has a 12-month low of $20.84 and a 12-month high of $33.11. The firm’s market cap is $1.01 billion.
Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings results on Wednesday, August 2nd. The medical device company reported $0.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.07. Cardiovascular Systems had a negative net margin of 0.87% and a positive return on equity of 0.89%. The business had revenue of $52.90 million for the quarter, compared to analysts’ expectations of $51.98 million. During the same period in the prior year, the company posted ($0.15) EPS. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. On average, equities research analysts predict that Cardiovascular Systems will post $0.04 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was posted by BBNS and is the sole property of of BBNS. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://baseballnewssource.com/markets/cardiovascular-systems-inc-csii-given-average-recommendation-of-buy-by-analysts-updated-updated-updated/1197214.html.
Large investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP boosted its stake in Cardiovascular Systems by 142.3% in the first quarter. Quantbot Technologies LP now owns 5,323 shares of the medical device company’s stock valued at $150,000 after buying an additional 3,126 shares in the last quarter. Winslow Evans & Crocker Inc. purchased a new stake in Cardiovascular Systems during the first quarter valued at about $153,000. Old Mutual Global Investors UK Ltd. purchased a new stake in Cardiovascular Systems during the first quarter valued at about $163,000. BNP Paribas Arbitrage SA boosted its stake in Cardiovascular Systems by 160.7% in the second quarter. BNP Paribas Arbitrage SA now owns 5,135 shares of the medical device company’s stock valued at $166,000 after buying an additional 3,165 shares in the last quarter. Finally, Clinton Group Inc. purchased a new stake in Cardiovascular Systems during the first quarter valued at about $212,000. 75.15% of the stock is currently owned by institutional investors.
About Cardiovascular Systems
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with our FREE daily email newsletter.